Advertisement
The objective of BioPharm America(TM) 2008 is to provide executives frompharmaceutical and biotechnology companies the opportunity to meetface-to-face and discuss potential strategic relationships and the latestindustry trends. The event is expected to draw over 400 top level businessdevelopment executives from approximately 65 companies across thepharmaceutical and biotechnology industries.
Advertisement
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell deathin mammals (apoptosis) to determine if its technology is applicable in humanmedicine. Accelerating apoptosis may have applications to the development ofcancer treatments. Delaying apoptosis may have applications to certaindiseases such as glaucoma, ischemia and arthritis, among others. Senescotakes its name from the scientific term for the aging of plant cells:senescence. The Company has developed technology that regulates the onset ofcell death. Delaying cell breakdown in plants extends freshness afterharvesting, while increasing crop yields, plant size and resistance toenvironmental stress for flowers, fruits and vegetables. In addition to itshuman health research programs, the Company believes that its technology canbe used to develop superior strains of crops without any modification otherthan delaying natural plant senescence. Senesco has partnered withleading-edge companies engaged in agricultural biotechnology and earnsresearch and development fees for applying its gene-regulating platformtechnology to enhance its partners' products. Senesco is headquartered in NewBrunswick, N.J.
Certain statements included in this press release are forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Actual results could differ materially from such statements expressedor implied herein as a result of a variety of factors, including, but notlimited to: the development of the Company's gene technology; the approval ofthe Company's patent applications; the successful implementation of theCompany's research and development programs and joint ventures; the success ofthe Company's license agreements; the successful conversion of the Company'sletter of intent into a license agreement; the acceptance by the market of theCompany's products; success of the Company's preliminary studies andpreclinical research; competition and the timing of projects and trends infuture operating performance, as well as other factors expressed from time totime in the Company's periodic filings with the Securities and ExchangeCommission (the "SEC"). As a result, this press release should be read inconjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this pressrelease, and the Company undertakes no obligation to publicly update suchforward-looking statements to reflect subsequent events or circumstances.
SOURCE Senesco Technologies, Inc.
